NRG
TAK icon

Nemes Rush Group’s Takeda Pharmaceutical TAK Stock Holding History

Nemes Rush Group’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.71K Hold
169
– – ﹤0.01% 748
2026
Q1 		$3.13K Hold
169
– – ﹤0.01% 688
2025
Q4 		$2.63K Buy
+169
New +$2.42K ﹤0.01% 695
2024
Q2 		– Sell
-3,003
Closed -$41.7K – 674
2024
Q1 		$41.7K Buy
3,003
+282
+10% +$4.1K 0.01% 296
2023
Q4 		$38.8K Hold
2,721
– – 0.01% 293
2023
Q3 		$42.1K Hold
2,721
– – 0.01% 270
2023
Q2 		$42.7K Buy
+2,721
New +$44.6K 0.01% 283

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Nemes Rush Group's TAK Position: Q2 2026 in Review

Nemes Rush Group held its Takeda Pharmaceutical (TAK) position steady in Q2 2026 at 169 shares worth $2.71K. The position accounts for ﹤0.01% of the portfolio, ranked #748.

Nemes Rush Group first reported a position in TAK in Q2 2023 and has held it in 7 quarters since. The position peaked at $42.7K in Q2 2023. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Nemes Rush Group held 169 shares of Takeda Pharmaceutical worth $2.71K as of Q2 2026.
  • Nemes Rush Group left its Takeda Pharmaceutical share count unchanged in Q2 2026.
  • Takeda Pharmaceutical made up ﹤0.01% of Nemes Rush Group's portfolio in Q2 2026, its #748 holding.
  • Nemes Rush Group first reported a position in Takeda Pharmaceutical in Q2 2023 and has held it in 7 quarters since.
  • Nemes Rush Group's Takeda Pharmaceutical position peaked at $42.7K in Q2 2023.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Nemes Rush Group's 13F filing for Q2 2026, filed 14 Aug 2026.